“Renal PK Study of LC350189”
This is a Phase 1, open-label, parallel-group, multiple-dose study designed to assess the effect of renal impairment on the PK and PD of LC350189.
Drug - LC350189 200 mg
Study drug in capsule form, take two capsules of LC350189 100mg, by oral, once daily, from Day 1 through 7
A Phase 1, Open-Label, Multiple-Dose Study to Evaluate the Pharmacokinetics and Pharmacodynamics of LC350189 in Subjects With Varying Degrees of Renal Impairment